The drug is being marketed under the brand names SEMAGLYN, MASHEMA and ALTERME
July 1, 2026 Nearly 4,000 GLP-1 Lawsuits Now Pending in Two MDLs There are now 3,848 lawsuits pending in the federal GLP-1 gastrointestinal injury MDL and another 146 cases in the separate NAION vision loss MDL
Some people also notice bloating, mild reflux, or changes in how quickly they feel satisfied when eating
Safety Considerations: As with any medication affecting metabolic functions, patients should discuss potential effects on sexual function with their healthcare providers
Study Design and Methods The authors investigated three prostate cancer cell lineshuman androgen receptor (AR)-positive 22Rv1, AR-negative DU145, and murine Myc-CaPtreated with recombinant IGF-1 (30 nM for 24 h)